GSK has disclosed encouraging results from its phase III DREAMM-7 trial, revealing that Blenrep (belantamab mafodotin) has shown effectiveness as a second-line treatment for relapsed or refractory multiple myeloma. The trial, which compared Blenrep plus BorDex to daratumumab plus BorDex, involved 494 patients who had previously undergone therapy but experienced disease progression. The independent review recommended early unblinding due to promising interim outcomes, with Blenrep demonstrating a significant improvement in progression-free survival (PFS) and a positive overall survival (OS) trend.
The study's primary endpoint of PFS was met, and further analyses are ongoing to assess other key measures such as OS, duration of response, and rates of minimal residual disease negativity. GSK's team, led by Hesham Abdullah, is preparing to present detailed findings from the interim analysis soon.
Blenrep's mechanism involves targeting the B-cell maturation antigen to deliver auristatin F, a cytotoxic agent, using technologies licensed from Seagen Inc. and BioWa Inc. This innovative approach aims to address the challenges of treating multiple myeloma, which is often considered manageable but not curable.
With the safety profiles consistent with previous data, GSK anticipates communicating these findings with health authorities for potential further action. For detailed safety information regarding Blenrep's use in the European Union, stakeholders are referred to consult the European Medicines Agency (EMA) reference guide provided by GSK.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.